Opus Genetics Share Holder Equity 2010-2024 | IRD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Opus Genetics share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Opus Genetics share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$169.8B
Vertex Pharmaceuticals (VRTX)	$121.4B
Gilead Sciences (GILD)	$109.7B
Bristol Myers Squibb (BMY)	$106.4B
Regeneron Pharmaceuticals (REGN)	$102.2B
CSL (CSLLY)	$92.8B
GSK (GSK)	$79.1B
Alnylam Pharmaceuticals (ALNY)	$36.5B
Argenex SE (ARGX)	$33.1B
BioNTech SE (BNTX)	$27.1B
Biogen (BIIB)	$26.7B
Illumina (ILMN)	$23.3B
Moderna (MRNA)	$21.2B
BeiGene (BGNE)	$21.1B
Genmab (GMAB)	$15.3B
Incyte (INCY)	$14.2B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$12.9B
Sarepta Therapeutics (SRPT)	$12.4B
Insmed (INSM)	$12.2B
Vaxcyte (PCVX)	$11.8B
Bio-Techne Corp (TECH)	$11.2B
QIAGEN (QGEN)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.3B
Roivant Sciences (ROIV)	$8.6B
Revolution Medicines (RVMD)	$8.4B
Legend Biotech (LEGN)	$8.3B
Exelixis (EXEL)	$8.2B
Viking Therapeutics (VKTX)	$8.2B
Intra-Cellular Therapies (ITCI)	$8.1B